These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1947760)

  • 1. Serum markers for breast cancer.
    Stenman UH; Heikkinen R
    Scand J Clin Lab Invest Suppl; 1991; 206():52-9. PubMed ID: 1947760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer.
    Eskelinen M; Tikanoja S; Brown J
    Anticancer Res; 1990; 10(4):959-62. PubMed ID: 2382995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of serum CA549, CA M26 and CA M29 levels in the post-operative follow-up of breast cancer patients.
    Nicolini A; Ferdeghini M; Colombini C; Carpi A
    J Nucl Med Allied Sci; 1990; 34(4):309-13. PubMed ID: 2090796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Is follow-up of breast cancer with CEA and CA 15-3 justified?].
    Fritsche E; Benz J
    Helv Chir Acta; 1992 May; 59(1):225-9. PubMed ID: 1526832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
    Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
    Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum marker combinations in human breast cancer (review).
    Lamerz R; Stieber P; Fateh-Moghadam A
    In Vivo; 1993; 7(6B):607-13. PubMed ID: 8193281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
    Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W
    Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.
    al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ
    Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of a new tumour marker TAG 12 in breast cancer.
    Eskelinen M; Hippeläinen M; Carlsson L; Jonsson P
    Anticancer Res; 1991; 11(2):805-8. PubMed ID: 2064336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [CA 15-3 and CEA as tumor markers in the diagnosis of the recurrence of breast cancer].
    Engel K; Schmid H; Hanke J; Kaufmann M; Müller A
    Geburtshilfe Frauenheilkd; 1988 May; 48(5):309-12. PubMed ID: 3165077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MCA performance in preoperative breast cancer patients.
    Donadeo A; Micelli G; Quaranta M; Atlante A; Schittulli F
    Anticancer Res; 1995; 15(2):527-9. PubMed ID: 7763034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How can treatment response be measured in breast cancer patients?
    van Dalen A; van der Linde DL; Heering KJ; van Oudalblas AB
    Anticancer Res; 1993; 13(5C):1901-4. PubMed ID: 8267398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer-associated antigen CA 15-3 in the diagnostics of breast tumours.
    Eskelinen M; Tikanoja S; Valkamo E; Loikkanen M; Collan Y
    Scand J Clin Lab Invest; 1988 Nov; 48(7):653-8. PubMed ID: 3201097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
    Jiang XT; Tao HQ; Zou SC
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum tumor markers in colorectal cancer staging, grading, and follow-up.
    Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A
    J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The serum tumor marker M3/M21 in the follow-up of breast cancer patients.
    Tempfer C; Hanzal E; Zeillinger R; Koelbl H; Dadak C; Kainz C
    Anticancer Res; 1996; 16(5B):3049-52. PubMed ID: 8920765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
    Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
    Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor markers in breast cancer (review).
    Jotti GS; Bombardieri E
    Anticancer Res; 1990; 10(1):253-8. PubMed ID: 2185687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tumor markers in the diagnosis and prognosis of breast cancer].
    Seliuzhitskiĭ IV; Skvortsov SV; Lytsar BN; Khomenko LP
    Klin Med (Mosk); 1993; 71(2):25-7. PubMed ID: 8046917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [MCA and CA 15-3 in the follow-up of patients with breast cancer].
    Hammer J; Track C; Hohenwallner W; Seewald DH; Zoidl JP; Wimmer E
    Strahlenther Onkol; 1992 Feb; 168(2):102-6. PubMed ID: 1542844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.